Mahmoud Rafieian-Kopaei
1, Hamid Nasri
2*1 Medical Plants Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran
2 Department of Nephrology, Division of Nephropathology, Isfahan University of Medical Sciences, Isfahan, Iran
*Corresponding Author: *Corresponding author: Professor Hamid Nasri, Department of Nephrology, Division of Nephropathology, Isfahan University of Medical Sciences, Isfahan, Iran. Tel: +983112208081, Fax: +98311223 5043, , Email:
hamidnasri@med.mui.ac.ir
Implication for health policy/practice/research/medical education
Diabetic nephropathy is a major risk of end-stage kidney failure and is associated with greater morbidity and mortality, predominantly with augmented cardiovascular disease. Many complex factors relate to the progression of nephropathy of diabetic patients .Current investigations have focused on the optimization of renin-angiotensin system blockade in patients with diabetic nephropathy using combinations of drugs that target this pathway, however further studies have focused on the potential of new therapies that either target various pathways up-regulated by hyperglycemia or other targets believed to promote progression of diabetic nephropathy.
Please cite this paper as: Rafieian-Kopaei M, Nasri H. Vitamin D therapy in diabetic kidney disease. J Nephropharmacol 2014; 3(1): 3-4.